. 2018 Oct 27;145(1):241–251. doi: 10.1007/s00432-018-2779-1

Table 3.

Patients with detectable KRAS oncogene point mutations in codon 12 in at least one of five analyzed cancer tissue samples with occurrence of homogenous or inhomogeneous distribution of KRAS mutation over the cancer tissue

Fraction of KRAS mutation positive cancer samples	Number of NSCLC patients	Histological diagnosis	KRAS mutation distribution over the cancer tissue
Fraction of KRAS mutation positive cancer samples	Number of NSCLC patients	SSC/ADC/ADSCC/LCNEC	Homogeneous	Inhomogeneous
5/5	27	16/10/0/1	27	0
4/5	2	0/2/0/0	0	2
3/5	1	0/0/0/1	0	1
2/5	1	0/1/0/0	0	1
1/5	1	0/0/1/0	0	1
Overall	32	16/13/1/2	27	5

Thirty-two of 51 NSCLCs revealed mutated KRAS gene (point mutations at codon 12) in at least one of all five samples harvested at surgery. Inhomogeneous distribution of KRAS point mutation was noted when not all of five analyzed samples of cancer tissue had detectable mutation

NSCLC non-small cell lung cancer, SCC squamous cell carcinoma, ADC adenocarcinoma, ADSCC adenosquamous cell carcinoma, LCNEC large cell neuroendocrine carcinoma